BCA-1, A B-cell chemoattractant signal, is constantly expressed in cutaneous lymphoproliferative B-cell disorders. by Mori, M. et al.
BCA-1, A B-cell chemoattractant signal, is constantly expressed
in cutaneous lymphoproliferative B-cell disorders
M. Moria, C. Manuellia, N. Pimpinellia,*, B. Bianchia, C. Orlandob, C. Maviliac,
P. Cappugia, E. Maggic, B. Giannottia, M. Santuccid
aDepartments of Dermatological Sciences, University of Florence Medical School, Via degli Alfani, 37, 50121 Firenze, Italy
bClinical Pathophysiology—Clinical Biochemistry Unit, University of Florence Medical School, Via degli Alfani, 37, 50121 Firenze, Italy
cInternal Medicine—Section Immunoallergology, University of Florence Medical School, Via degli Alfani, 37, 50121 Firenze, Italy
dHuman Pathology and Oncology, University of Florence Medical School, Via degli Alfani, 37, 50121 Firenze, Italy
Received 13 August 2002; received in revised form 11 February 2003; accepted 11 April 2003Abstract
We analysed the immunophenotypic and molecular expression of BCA-1 (B-cell-specific chemokine) and CXCR5 (BCA-1
receptor) in normal skin and different cutaneous lymphoproliferative disorders (cutaneous T-cell lymphoma (CTCL); cutaneous
B-cell lymphoma (CBCL); cutaneous B-cell pseudolymphoma (PCBCL)), with the aim of investigating their possible involvement in
the pathogenesis of cutaneous B-cell disorders. BCA-1 and CXCR5 were constantly expressed in CBCL and PCBCL, but not in
normal skin and CTCL. BCA-1 and CXCR5 were constantly coexpressed by CD22+ B-cells, while CD35+ follicular dendritic
cells coexpressed BCA-1 in PCBCL cells only. In low grade CBCL, as compared with high grade CBCL, the intensity of CXCR5
expression on neoplastic CD22+ cells was lower than that of BCA-1. The image analysis of reverse transcriptase-polymerase chain
reaction (RT-PCR) products showed a significant quantitative difference between PCBCL/low grade CBCL and high grade CBCL.
The above findings, although only observed in a small series of patients, are in keeping with findings in MALT gastric and gastric
MALT lymphomas, adding further evidence of the close similarities between CBCL and MALT lymphomas.
# 2003 Elsevier Ltd. All rights reserved.Keywords: Skin, Lymphoma, Pseudolymphoma, B-cell, Chemokine1. Introduction
Recent progress in chemokine (chemoattractant cyto-
kine) research has greatly advanced the understanding
of the migration properties of lymphoid cells. Two
functionally distinct subfamilies of chemokines, referred
as ‘‘inflammatory’’ and ‘‘housekeeping’’ chemokines,
have recently been recognised [1–4]. While the former
are produced by activated tissue cells and leucocytes at
sites of inflammation, the latter regulate the localisation
of lymphoid cells during lymphopoiesis, antigen-priming
and immune surveillance [1–4]. B-cells show a high
capacity to recirculate between blood, lymphoid and
extralymphoid compartments [5–7]. By contrast to
T-cells, migration responses of B-cells to chemokines are
not well characterised, although data from the currentliterature indicate that both housekeeping and inflam-
matory chemokines act on B-cells [8–10]. The recently
discovered chemokine, BCA-1 (also regarded as CXCL13),
is the most effective B-cell chemoattractant [11–12]. It
selectively binds to CXCR5, a chemokine receptor with
predominant expression on blood and tonsillar B-cells,
as well as on a subset of memory CD4+ T-cells [13].
It has recently been demonstrated that both BCA-1
and CXCR5 are highly expressed in Helicobacter pylori
(Hp)-induced Mucosa-Associated Lymphoid Tissue
(MALT) lymphoma, showing a distinctive pattern of
expression [14]. This findings suggest a possible patho-
genic role for BCA-1 in the natural history of MALT
lymphoma. No information is currently available con-
cerning the expression of BCA-1 and CXCR5 in cutaneous
lymphoproliferative disorders. The clinico-pathological
features of primary cutaneous B-cell lymphomas
(CBCL) are extensively dealt with elsewhere in Refs.
[15–18]. In short, CBCL are mostly characterised by a0959-8049/03/$ - see front matter # 2003 Elsevier Ltd. All rights reserved.
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homogeneous clinical presentation and behaviour, with
a good response to local radiotherapy, low tendency to
extracutaneous spread and excellent prognosis. Accord-
ing to the European Organization for Research and
Treatment of Cancer (EORTC) classification of primary
cutaneous lymphomas [19], CBCL are divided into
three subgroups. So-called follicular centre cell (FCC)
lymphoma and immunocytoma (IC)/marginal zone
lymphoma (MZL), due to putative histological simila-
rities with their purported nodal counterparts, and they
have an indolent clinical behaviour. These entities, FCC
and IC/MZL, are regarded as follicular lymphoma and
extranodal MZL (MALT-type lymphoma), respectively,
in the World Health Organization (WHO) classification
of lymphoid neoplasms [20]. The different morphologies
are often found in different lesions of the same patient
or even in different areas of the same lesion and this
hampers their strict categorisation into specific sub-
groups, such as FCC lymphoma and IC/MZL. An
alternative possibility of a unitary interpretation of low
grade CBCL has been suggested. In fact, we have
documented that the histological pattern in CBCL is
largely related to the age and growth rates of the skin
lesions [15–18], with a characteristic multiphasic pro-
gression of the histological/immunohistological pattern
from ‘‘early’’ (patchy/nodular infiltrate, with distinct
compartmentalisation of neoplastic, small-medium cen-
trocyte-like B-cells and reactive T-cells, that are often
prominent) to ‘‘late’’ phases (diffuse infiltrate of neo-
plastic, large transformed centrocyte-like B-cells, with
few admixed reactive T-cells). These multiphasic histo-
logical features have no correlation with either the clinical
course or the prognosis of the disease. Moreover, most
CBCL—despite variable morphological features—show
a rather uniform immunophenotype (CD5-, CD10-) and
genotype (lack of bcl-1/bcl-2 and c-myc gene rearrange-
ments) of the neoplastic cells. The close similarities
between primary CBCL and MALT lymphomas and
the evidence for an acquired B-cell arm of Skin-Asso-
ciated Lymphoid Tissue (SALT) [21] led us to tenta-
tively designate these CBCL as SALT-related B-cell
lymphomas [16,18]. Recently, however, more refined
definitions of FCC lymphoma [22] and MZL [23] have
been suggested, as the prerequisite for a better clinico-
pathological differential diagnosis. Subtle classification
problems apart, in this paper we will refer to this pro-
minent group of CBCL as ‘‘low grade CBCL’’. In addi-
tion, a third, much smaller subgroup with intermediate
prognosis (the so-called large B-cell lymphoma of the
leg) is identified in the EORTC classification [21,24].
The clinicopathological significance of this group of
primary CBCL is currently debated. In fact, all the
major investigators and groups coworking in the
EORTC Cutaneous Lymphoma Task Force agree that
CBCL, characterised by a rapid growth of skin lesions;
large ‘‘round’’ cell histology (i.e., centroblast- andimmunoblast-like), high proliferation rate, and bcl-2
protein expression at presentation, do occur more
rarely. Their possible predilection for the elderly (>70
years of age) and the selected skin sites (lower legs) and,
more importantly, their worse prognosis have been
investigated in a larger series in a EORTC multicentre
study. The results of this study suggest that de novo
large ‘‘round’’ cell histology, age >70 years, and loca-
tion on the legs are significantly associated with a worse
prognosis [25]. However, in the WHO classification,
diffuse large cell lymphomas (DLCL) of the B-cell ori-
gin are grouped together, without any distinction with
regard to the specific site of onset on the skin [20]. In
this paper, we will refer to CBCL with de novo large
round cell histology as ‘‘high grade CBCL’’.
By the combined use of different methods, including
immunohistochemistry, 2-colour immunofluorescence,
and molecular analysis (reverse transcriptase-polymerase
chain reaction (RT-PCR) and in situ hybridisation), we
have analysed the phenotypic and genotypic expression
of BCA-1 and CXCR5 in normal skin and different
cutaneous lymphoproliferative disorders—CBCL, cuta-
neous B-cell pseudolymphoma (PCBCL, defined as
reactive, polyclonal lymphoid hyperplasia with a pro-
minent B-cell component), and cutaneous T-cell lym-
phoma (CTCL), in order to investigate the possible
involvement of these molecules in the pathogenesis of
B-cell disorders of the skin. In addition, we examined
the relevance of their possible differential expression in
the different subcategories (PCBCL versus low grade
CBCL versus high grade CBCL).2. Materials and methods
2.1. Patients and skin samples
The 17 lesional skin samples, consisting of 6-mm
punch biopsies, were obtained under local anaesthesia
from: 3 patients with PCBCL (insect bite-related); 10
patients with CBCL (7 low grade, classified as MZL
according to the EORTC and extranodal MZL accord-
ing to the WHO classification; 3 high grade, DLCL, two
of which were located on the legs and one on the back),
and 4 patients with CTCL (Mycosis Fungoides). Con-
trol, healthy skin samples were also obtained from 5
patients who underwent cosmetic surgery.
Each tissue specimen was in part formalin-fixed and
paraplast-embedded for routine histological exami-
nation; in part embedded in O.T.C. (‘‘Tissue Tek’’,
Miles Scientific, Naperville, IL), snap frozen and stored
at 80 C until sectioning for use in immunohisto-
chemistry (IHC); 2-colour immunofluorescence; (2c-IF),
and in situ hybridisation (ISH); and in part prepared for
molecular analysis (Reverse Transcriptase-Polymerase
Chain Reaction, RT-PCR). The specimens were put in a1626 M. Mori et al. / European Journal of Cancer 39 (2003) 1625–1631
RNase-free microfuge, and immediately frozen in liquid
nitrogen until RNA extraction.
2.2. Immunohistochemistry (IHC)
Immunohistochemical staining was performed on 7
mm cryostat sections by using the Alkaline phosphatase
and anti-alkaline phosphatase (APAAP) method, as
previously described in Ref. [26]. The monoclonal anti-
bodies used were mouse anti-human CD3, CD4, CD8,
CD19, CD22, CD35, CD45RO, kappa and lambda light
chains (Dako A/S Glostrup, Denmark), and BLC/BCA-
1/CXCl13, CXCR5/BLR-1 (R&D Systems, MN, USA).
Normal human lymph nodes were stained in parallel as
positive controls. Sections incubated with an irrelevant,
isotype-matched mouse antibody were used as negative
controls. The step section method was used to evaluate
the results; serial sections of each tissue specimen were
carefully and blindly evaluated by two of the authors.
For quantitative analysis, the stained cells in the dermal
infiltrate were counted in five consecutive microscopic
fields (250). The results were expressed as the mean
number of stained cells per 100 cells observed. Only cells
whose nuclei were contained in the plane of the section
were considered. The results were scored independently by
two observers, and the resulting figures were averaged.
2.3. Two-colour immunofluorescence (2c-IF)
Surface expression of BCA-1, CXCR5, CD22, and
CD35 was analysed by 2c-IF method using 5 different
experimental protocols: (1) phycoerythrin (PE)-con-
jugated MoAb mouse anti-human CXCR5, biotin-con-
jugated MoAb mouse anti-human BCA-1 and
fluorescein isothiocyanate (FITC)-conjugated avidin; (2)
MoAb mouse anti-human CD22, clone IgG1, PE-con-
jugated goat anti-mouse IgG1 polyclonal antibody,
biotin-conjugated MoAb mouse anti-human BCA-1 and
FITC-conjugated avidin; (3) MoAb mouse anti-human
CD22, clone IgG1, FITC-conjugated goat anti-mouse
IgG1 polyclonal antibody and PE-conjugated MoAb
mouse anti-human CXCR5; (4) MoAbmouse anti-human
CD35, clone IgG1, PE-conjugated goat anti-mouse IgG1
polyclonal antibody, biotin-conjugated Moab mouse
anti-human BCA-1 and FITC-conjugated avidin; (5)
MoAb mouse anti-human CD35, clone IgG1, FITC-
conjugated goat anti-mouse IgG1 polyclonal antibody
and PE-conjugated MoAb mouse anti-human CXCR5.
Negative control stains were performed by replacing the
primary antibody with an irrelevant isotype-matched
mouse MoAb and with chromogen only.
2.4. RNA extraction and RT-PCR
Total RNA was extracted from the skin biopsies.
Frozen tissues were ground to a powder with a pestleand mortar in liquid nitrogen before being added to a
RNAwiz (Ambion, Austin, TX ) for homogenisation.
All samples used in these experiments clearly showed
18S and 28S bands in a 0.8% agarose gel, indicating the
integrity of RNA. Following extraction, 1 mg of total
RNA was reverse-transcribed using M-MLV reverse
transcriptase (GIBCO-BRL, Gaithersberg, MD) accord-
ing to the manufacturer’s instructions. All cDNAs were
amplified with primers for -actin [27]: sense 50-CCT
CGC CTT TGC CGA TCC; antisense 30-GGA TCT
TCA TGA GGT AGT CAG TC) to test the quality of
cDNAs. PCR products were electrophoresed in an
agarose gel and measured by image analysis. Different
amounts of cDNA for each sample (corresponding to
the same amount of -actin) were co-amplified with
primers for -actin (626 bp) and for BCA-1 (368 bp) and
CXCR5 (318 bp) in the same reaction and distinguished
using gel electrophoresis by the differences in the pro-
duct length. PCR amplification were performed using
the primers for BCA-1: sense 50-GGG CTGCAGCTC-
CAGACAGAATGAAGTTC, antisense 30-GGA CTC
GAG TGG AAA TAT CAG CAT CAG G [28] and for
CXCR5: sense 50 ACG CTG GAA ATG GAC CTC
GAG AAC CTG GAG; antisense 30 AGA AGT AGA
ACG GGA AAC GGC ACC GG. Primers for CXCR5
were selected using the Oligo Primer Analysis Software
Version 5.0 (National Bioscience, Inc. Plymouth, MN,
USA). All other primers were purchased from MWG
Biotech AG (Ebersberg, Germany). In all PCR reac-
tions, a positive control and 2 negative controls (one
omitting the reverse transcription without the RT
enzyme, another without cDNA as a template to exclude
contamination) were included. We used human genomic
DNA as a template in the PCR amplification to confirm
that the product was not due to pseudogene sequences.
Each sample was subjected to 25 cycles of amplification
using 10 pM of each primer with 0.25 units of Taq
DNA in 25 ml final volume of reaction mix. The cycling
conditions were 94 C for 30 s (denaturation), 64 C for
30 s (annealing) and 72 C for 40 s (elongation). Before
the first cycle, samples were denaturated at 94 C for 2
min and, after the last cycle, samples were subjected to a
final elongation step of 72 C for 2 min. PCR products
were electrophoresed on a 2% agarose gel and visual-
ised by ethidium bromide staining. The size of the
amplified products was evaluated by comparison with
molecular weight markers run in parallel lanes.
2.5. Image analysis of PCR products
The intensity of the bands obtained by PCR amplifi-
cation were measured by a CCD video camera C3077/01
Hamamatsu Photonics (Japan) connected with the
video frame grabber M4476 (Hamamatsu Photonics
Japan), in a computer Macintosh IIsi (Apple, USA).
Acquisition of the image was obtained with ImagequestM. Mori et al. / European Journal of Cancer 39 (2003) 1625–1631 1627
IQBase software by Hamamatsu Photonics (Japan).
Image processing and analysis was performed with the
free software IMAGE by Wayne Rasband, National
Institutes of Health Research Services Branch NIMH,
version 1.28.
2.6. In situ hybridisation (ISH)
Probes for BCA-1 (368bp) and CXCR5 (312bp) were
obtained by PCR amplification, and sequenced. DNAfragments were subcloned using the pGEM-T Vector
system (Promega Co. Madison, WI) according to the
manufacturer’s instruction. Sequences of the subcloned
products were obtained using the Cy5TMAuto-
readTMSequencing kit (Pharmacia Biotech, Uppsala,
Sweden) and automatically sequenced (Pharmacia Bio-
tech, Uppsala, Sweden). Probes were labelled using the
BrightStar Psoralen-Biotin labelling kit (Ambion,
Austin, TX) and ISH were performed using DAKO
GenPoint (Dako A/S Glostrup, Denmark) according toFig. 1. Two-colour immunofluorescence detection of BCA-1, CXCR5, CD22 and CD35 expression in PCBCL, low grade CBCL and high grade
CBCL. PCBCL (original magnification 100): heavy CD35+ staining of dendritic cells and, to a lesser extent, lymphoid cells within follicles (1a,
top left); dendritic cells coexpress BCA-1 (1b, top right). Low grade CBCL (original magnification 100): BCA-1 expression (1c, middle left) is
restricted to clustered CD22+ B-cells (1d, middle right). High grade CBCL (original magnification 400): large neoplastic cells show substantial
expression of BCA-1 (1e, bottom left) and CXCR5 (1f, bottom right).1628 M. Mori et al. / European Journal of Cancer 39 (2003) 1625–1631
the manufacturer’s instructions. Negative control stains
were performed by replacing the labelled probe with
hybridisation buffer.3. Results
3.1. IHC and 2c-IF
BCA-1 and CXCR5 expression was not detected in
either clinically healthy skin or CTCL. In contrast,
BCA-1 and CXCR5 expression was found in all of the
biopsies from PCBCL (3/3) and CBCL (10/10).
By both IHC (according to the step-section analysis)
and 2c-IF, a different pattern and intensity of expression
was observed among the PCBCL, low grade CBCL and
high grade CBCL samples. In PCBCL, that were con-
stantly characterised by a polyclonal B-cell infiltrate
that was often arranged in well structured lymphoid
follicles, BCA-1 and CXCR5 expression was clear cut
and restricted to CD22+ B-cells; BCA-1 was also
expressed by CD35+ dendritic cells within follicles
(Fig. 1a and b). In low grade CBCL, BCA-1 expression
was also clear cut and restricted to CD22+ B-cells,
either clustered (Fig. 1c and d) or sparsely distributed
within the often strongly T-cell reactive infiltrate. No
dendritic staining pattern of BCA-1 was observed in
neoplastic, follicle-like B-cell clusters. In these latter
cells, CXCR5 expression was less than in the reactive
follicles found in PCBCL. In all high grade CBCL, that
were virtually composed of monoclonal large cells
only, BCA-1 and CXCR5 were highly expressed (Fig. 1e
and f).
3.2. RT-PCR and quantitative analysis
BCA-1 and/or CXCR5 were never detected by
RT-PCR in either clinically healthy skin or CTCL sam-
ples. On the contrary, BCA-1 and CXCR5 signals were
detected in all of the CBCL and PCBCL samples. The
image analysis of the intensity of bands of -actin,
BCA-1 and CXCR5 obtained with RT-PCR showed a
different level of expression for BCA-1 and CXCR5: the
intensity of bands from high grade CBCL was clearly
higher than that from low grade CBCL and PCBCL
samples (Figs. 2 and 3).
3.3. In situ hybridisation
No in situ hybridisation of BCA-1 and CXCR5 was
found in either the clinically healthy skin or CTCL
samples. On the contrary, BCA-1 and CXCR5 staining
was observed in pseudoCBCL and CBCL (Fig. 4). In
particular, the expression was more evident in the high
grade CBCL.4. Discussion
In this study, we have analysed the phenotypic and
genotypic expression of BCA-1 and CXCR5 in CBCL
and PCBCL, in order to investigate the possible invol-
vement of these molecules in the pathogenesis of theseFig. 2. Reverse transcriptase-polymerase chain reaction (RT-PCR) for
-actin, BCA-1 and CXCR5. Lane 1: co-amplification of -actin
(upper band: 626 bp) and BCA-1 (lower band: 368 bp) in a repre-
sentative case of CBCL. Lane 2: co-amplification of -actin (upper
band: 626 bp) and CXCR5 (lower band: 318 bp) in the same CBCL
case. No expression of BCA-1 (Lanes 3 and 5) and CXCR5 (Lanes 4
and 6) in CTCL and healthy skin (HS), respectively. K- : negative
control for primers. bp: base pair.Fig. 3. Image quantitative analysis of RT-PCR products: diagram of
BCA-1 and CXCR5 expression in pseudoCBCL (samples 1–3), low
grade CBCL (samples 7–13), and high grade CBCL (samples 4–6).
O.D., Optical Density.Fig. 4. In situ hybridisation (ISH, see Materials and Methods section
for technical details). Representative picture: BCA-1 staining in
CBCL, low grade. Original magnification, 160.M. Mori et al. / European Journal of Cancer 39 (2003) 1625–1631 1629
characteristic disorders. We also wanted to examine the
relevance of their possible differential expression in the
different subcategories (PCBCL versus low grade CBCL
versus high grade CBCL).
No expression of BCA-1 and CXCR5 was found at the
immunohistochemical andmolecular level in biopsies from
either clinically healthy skin or CTCL, thus confirming the
B-cell restricted specificity of these chemokines.
Interestingly, significant differences were found among
the PCBCL, low grade CBCL and high grade CBCL. In
fact, although the expression of CXCR5 and BCA-1 was
restricted to CD22+ B-cells in all of the examined spe-
cimens, CD35+/BCA-1+ dendritic cells were found by
2c-IF in lymphoid follicles of PCBCL only. In low
grade CBCL, conversely, virtually no CD35+ dendritic
cells coexpressed BCA-1, and the intensity of CXCR5
expression on CD22+ cells was lower than that of
BCA-1. In high grade CBCL, both BCA-1 and CXCR5
were strongly expressed by neoplastic CD22+ B-cells.
In particular, the intensity of CXCR5 was much higher
than that observed in low grade CBCL.
The above findings, although only in a small series of
patients, are in keeping with those evidenced in Helico-
bacter pylori (HP)-induced MALT (gastritis) and gastric
lymphoma, MALT type (14). In fact, the distribution
and intensity of BCA-1 and CXCR5 in (secondary)
lymphoid follicles of PCBCL parallel those found in
HP-induced MALT (gastritis) [14]. On the other hand,
the expression of BCA-1 and CXCR5 was virtually
restricted to neoplastic B-cells in CBCL, as well as in
gastric lymphomas [14]. In addition, in both high grade
CBCL and high grade gastric lymphomas, BCA-1
and—even more so—CXCR5 expression by large blasts
was very pronounced [14]. An interesting issue for
debate is the absence of dendritic staining for BCA-1 in
both low grade CBCL and low grade gastric lympho-
mas [14]. In this latter group, we have interpreted this
finding as reflecting the absence of follicular dendritic
cells from the neoplastic infiltrate (CD21- and CD23-
negative staining on paraffin sections). In low grade
CBCL, conversely, we usually found CD35+ follicular
dendritic cells, with a stronger staining in cryostat sec-
tions, while the expression of CD21 is  in cryostat
sections and often lacking in paraffin sections. Indeed,
we have previously stressed this ‘‘aberrancy’’ of den-
dritic cells in neoplastic follicle-like clusters of classic
CBCL [15–18,29,30]. Therefore, it is not unlikely that
immunologically aberrant follicular dendritic cells have
a substantially downregulated expression of BCA-1 in
both low grade CBCL and low grade gastric lymphoma
of the MALT type.
Taken altogether, the findings described in this paper
add to the evidence of close similarities between CBCL
(primary cutaneous B-cell lymphoma) and MALT lym-
phomas, with chronic antigen stimulation as a possible
common pathogenic denominator [14,21].Acknowledgements
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